Polyclinique de l'Ormeau

Running trials

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

  NCT06625970· Phase 3· Source

• Active, not recruiting

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· Phase 2· Source

• Recruiting

  AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

  NCT05002556· Source

• Recruiting

  PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

  NCT04790253· Source

• Recruiting

  Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  NCT04747054· Phase 3· Source

• Recruiting

  Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

  NCT04325425· Phase 2· Source

• Recruiting

  A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

  NCT04299646· Phase 2· Source

• Recruiting

  PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer

  2024-512173-27-00· Phase 3· Source

• Active, not recruiting

  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  NCT03774732· Phase 3· Source

• Completed

  IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

  NCT02967289· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Immediate Effects of STENDO on the Walking Abilities of Patients with COPD (STENDO-COPD)

  NCT05618509· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Source